Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.

[1]  Michelle S. Miller,et al.  Targeting a neoantigen derived from a common TP53 mutation , 2021, Science.

[2]  Ying Liang,et al.  Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site. , 2020, Cancer cell.

[3]  W. El-Deiry,et al.  AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing , 2020, Cell Death Discovery.

[4]  D. Sallman.  To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia , 2020, Haematologica.

[5]  J. Esteve,et al.  MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia. , 2020, Future oncology.

[6]  T. Stiewe,et al.  p53’s Extended Reach: The Mutant p53 Secretome , 2020, Biomolecules.

[7]  Hui Sun,et al.  Role of post-translational modifications in regulation of tumor suppressor p53 function , 2020, Frontiers of Oral and Maxillofacial Medicine.

[8]  G. Mills,et al.  COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms , 2019, Clinical Cancer Research.

[9]  W. Gu,et al.  p53 β-hydroxybutyrylation attenuates p53 activity , 2019, Cell Death & Disease.

[10]  Jenny C. Chang,et al.  Cancer therapeutic targeting using mutant–p53-specific siRNAs , 2019, Oncogene.

[11]  Kiyotsugu Yoshida,et al.  Tumor suppressive role for kinases phosphorylating p53 in DNA damage‐induced apoptosis , 2018, Cancer science.

[12]  U. Pati,et al.  CHIP promotes autophagy‐mediated degradation of aggregating mutant p53 in hypoxic conditions , 2018, The FEBS journal.

[13]  S. Knappskog,et al.  High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma , 2018, BMC Cancer.

[14]  T. Massoud,et al.  A protein folding molecular imaging biosensor monitors the effects of drugs that restore mutant p53 structure and its downstream function in glioblastoma cells , 2018, Oncotarget.

[15]  K. Wiman,et al.  APR-246 reactivates mutant p53 by targeting cysteines 124 and 277 , 2017, Cell Death & Disease.

[16]  M. Barton,et al.  p53: emerging roles in stem cells, development and beyond , 2018, Development.

[17]  A. Verma,et al.  Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia , 2018, Science Translational Medicine.

[18]  Eric R. Wolf,et al.  Mutant and wild-type p53 form complexes with p73 upon phosphorylation by the kinase JNK , 2018, Science Signaling.

[19]  J. Espinosa,et al.  Mechanisms of transcriptional regulation by p53. , 2018 .

[20]  K. Engeland.  Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM. , 2018 .

[21]  Scott W. Lowe,et al.  Putting p53 in Context , 2017, Cell.

[22]  A. Blanden,et al.  Thiosemicarbazones Functioning as Zinc Metallochaperones to Reactivate Mutant p53 , 2017, Molecular Pharmacology.

[23]  V. Rotter,et al.  Differential regulated microRNA by wild type and mutant p53 in induced pluripotent stem cells , 2016, Cell Death and Disease.

[24]  P. Hainaut,et al.  Somatic TP53 Mutations in the Era of Genome Sequencing. , 2016, Cold Spring Harbor perspectives in medicine.

[25]  Dmitriy Sonkin,et al.  TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data , 2016, Human mutation.

[26]  P. Grossmann,et al.  Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks , 2016, Nucleic acids research.

[27]  Kowthar Y. Salim,et al.  COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo , 2016, Oncotarget.

[28]  M. Witcher,et al.  Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential. , 2016, Biochimica et biophysica acta.

[29]  W. El-Deiry,et al.  Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated ΔNp73 Inhibition and p73 Activation. , 2016, Cancer research.

[30]  G. Blandino,et al.  Oncogenic Intra-p53 Family Member Interactions in Human Cancers , 2016, Front. Oncol..

[31]  G. Calin,et al.  PDL1 Regulation by p53 via miR-34 , 2015, Journal of the National Cancer Institute.

[32]  D. Walerych,et al.  Mutant p53: One, No One, and One Hundred Thousand , 2015, Front. Oncol..

[33]  W. El-Deiry,et al.  Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53. , 2015, Cancer research.

[34]  A. Blanden,et al.  Synthetic Metallochaperone ZMC1 Rescues Mutant p53 Conformation by Transporting Zinc into Cells as an Ionophore , 2015, Molecular Pharmacology.

[35]  D. Proia,et al.  Improving survival by exploiting tumor dependence on stabilized mutant p53 for treatment , 2015, Nature.

[36]  I. Simon,et al.  The p53 C terminus controls site-specific DNA binding and promotes structural changes within the central DNA binding domain. , 2015, Molecular cell.

[37]  Che L. Martin,et al.  Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4 , 2015, Proceedings of the National Academy of Sciences.

[38]  V. Dötsch,et al.  Functional interplay between MDM2, p63/p73 and mutant p53 , 2014, Oncogene.

[39]  W. Pierceall,et al.  Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts) , 2014 .

[40]  X. Zou,et al.  Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives , 2014, OncoTargets and therapy.

[41]  Xiaoping Zhou,et al.  New insights into p53 functions through its target microRNAs. , 2014, Journal of molecular cell biology.

[42]  Karen H. Vousden,et al.  Mutant p53 in Cancer: New Functions and Therapeutic Opportunities , 2014, Cancer cell.

[43]  W. El-Deiry,et al.  Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53. , 2014, Cancer research.

[44]  Xuan Liu,et al.  Phosphorylation of p53 by TAF1 inactivates p53-dependent transcription in the DNA damage response. , 2014, Molecular cell.

[45]  C. Leonetti,et al.  A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells , 2013, Journal of experimental & clinical cancer research : CR.

[46]  G. Demetri,et al.  A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas , 2013, Clinical Cancer Research.

[47]  G. Kroemer,et al.  Chaperone-mediated autophagy degrades mutant p53. , 2013, Genes & development.

[48]  Jing Zhang,et al.  Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. , 2013, Journal of medicinal chemistry.

[49]  Milton L. Brown,et al.  Targeting Mutant p53 by a SIRT1 Activator YK-3-237 Inhibits the Proliferation of Triple-Negative Breast Cancer Cells , 2013, Oncotarget.

[50]  Alan R. Fersht,et al.  Small molecule induced reactivation of mutant p53 in cancer cells , 2013, Nucleic acids research.

[51]  Binh Vu,et al.  MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. , 2013, Cancer research.

[52]  T. Limpaiboon,et al.  Ratio disruption of the ∆133p53 and TAp53 isoform equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma. , 2013, International journal of oncology.

[53]  U. Moll,et al.  Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis , 2013, Cell Death and Differentiation.

[54]  Q. Sun,et al.  Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop , 2013, Oncogene.

[55]  A. Wellstein,et al.  Dietary downregulation of mutant p53 levels via glucose restriction , 2012, Cell cycle.

[56]  Jean-Yves Blay,et al.  Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. , 2012, The Lancet. Oncology.

[57]  H. Hermeking,et al.  MicroRNAs in the p53 network: micromanagement of tumour suppression , 2012, Nature Reviews Cancer.

[58]  D. Menendez,et al.  The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. , 2012, Cancer research.

[59]  C. Croce,et al.  Oncosuppressive role of p53‐induced miR‐205 in triple negative breast cancer , 2012, Molecular oncology.

[60]  S. Berberich,et al.  MicroRNA-34a Modulates MDM4 Expression via a Target Site in the Open Reading Frame , 2012, PloS one.

[61]  Carol Prives,et al.  Mutant p53: one name, many proteins. , 2012, Genes & development.

[62]  A. Lal,et al.  MicroRNAs, wild-type and mutant p53: More questions than answers , 2012, RNA biology.

[63]  D. Veprintsev,et al.  Specific Recognition of p53 Tetramers by Peptides Derived from p53 Interacting Proteins , 2012, PloS one.

[64]  A. Levine,et al.  Allele-specific p53 mutant reactivation. , 2012, Cancer cell.

[65]  S. Deb,et al.  Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. , 2012, Carcinogenesis.

[66]  P. Muti,et al.  MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function , 2011, Cell Death and Differentiation.

[67]  U. Moll,et al.  SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis , 2011, Cell Death and Differentiation.

[68]  Christopher A. Maher,et al.  A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial–mesenchymal transition , 2011, The Journal of cell biology.

[69]  V. de Laurenzi,et al.  Role of p63 in cancer development. , 2011, Biochimica et biophysica acta.

[70]  J. Bourdon,et al.  p53 Isoforms: An Intracellular Microprocessor? , 2011, Genes & cancer.

[71]  M. Mclaughlin,et al.  Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression , 2011, Cell.

[72]  Tae Jin Lee,et al.  p53 regulates epithelial–mesenchymal transition through microRNAs targeting ZEB1 and ZEB2 , 2011, The Journal of experimental medicine.

[73]  G. Melino,et al.  P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism , 2011, Oncogene.

[74]  F. Talos,et al.  Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells , 2011, Molecular Cancer Research.

[75]  Maik Friedrich,et al.  p53 activates the PANK1/miRNA-107 gene leading to downregulation of CDK6 and p130 cell cycle proteins , 2010, Nucleic Acids Res..

[76]  D. Malkin.  Li-fraumeni syndrome. , 2001, Genes & cancer.

[77]  M. Tada,et al.  Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells. , 2010, Biomedical research.

[78]  Wei Gu,et al.  p53 post-translational modification: deregulated in tumorigenesis. , 2010, Trends in molecular medicine.

[79]  Huey-Jen Lin,et al.  Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. , 2010, Cancer cell.

[80]  S. Bates,et al.  Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors , 2010, Expert review of anticancer therapy.

[81]  G. Sal,et al.  p53-family proteins and their regulators: hubs and spokes in tumor suppression , 2010, Cell Death and Differentiation.

[82]  R. Hruban,et al.  P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis , 2010, Proceedings of the National Academy of Sciences.

[83]  C. Harris,et al.  Clinical outcomes and correlates of TP53 mutations and cancer. , 2010, Cold Spring Harbor perspectives in biology.

[84]  D. Bashford,et al.  Identification and Characterization of the First Small Molecule Inhibitor of MDMX* , 2010, The Journal of Biological Chemistry.

[85]  Magali Olivier,et al.  TP53 mutations in human cancers: origins, consequences, and clinical use. , 2010, Cold Spring Harbor perspectives in biology.

[86]  T. Jacks,et al.  p63 and p73 Transcriptionally Regulate Genes Involved in DNA Repair , 2009, PLoS genetics.

[87]  T. Ichisaka,et al.  Suppression of induced pluripotent stem cell generation by the p53–p21 pathway , 2009, Nature.

[88]  Shwu‐Yuan Wu,et al.  Crosstalk between sumoylation and acetylation regulates p53‐dependent chromatin transcription and DNA binding , 2009, The EMBO journal.

[89]  B. Kopnin,et al.  p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway. , 2009, Cancer letters.

[90]  Hailong Wu,et al.  p53 represses c-Myc through induction of the tumor suppressor miR-145 , 2009, Proceedings of the National Academy of Sciences.

[91]  A. Fersht,et al.  Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2 , 2009, Oncogene.

[92]  H. Ke,et al.  p53 Oligomerization Is Essential for Its C-terminal Lysine Acetylation* , 2009, Journal of Biological Chemistry.

[93]  Maria Miller,et al.  Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation. , 2009, Structure.

[94]  M. Tagawa,et al.  Gene medicine for cancer treatment: Commercially available medicine and accumulated clinical data in China , 2008, Drug design, development and therapy.

[95]  Aimee L Jackson,et al.  Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. , 2008, Cancer research.

[96]  J. Lukin,et al.  Molecular basis of Pirh2-mediated p53 ubiquitylation , 2008, Nature Structural &Molecular Biology.

[97]  J. Milner,et al.  Influence of tetramerisation on site-specific post-translational modifications of p53: comparison of human and murine p53 tumour suppressor protein. , 2008, Cancer biology & therapy.

[98]  Frank M Boeckler,et al.  Targeted rescue of a destabilized mutant of p53 by an in silico screened drug , 2008, Proceedings of the National Academy of Sciences.

[99]  Roland L. Dunbrack,et al.  Oligomerization of BAK by p53 Utilizes Conserved Residues of the p53 DNA Binding Domain* , 2008, Journal of Biological Chemistry.

[100]  D. Bell,et al.  Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53 , 2008, PLoS genetics.

[101]  Yi Tang,et al.  Acetylation Is Indispensable for p53 Activation , 2008, Cell.

[102]  E. Feinstein,et al.  Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway , 2008, Proceedings of the National Academy of Sciences.

[103]  A. Strasser,et al.  In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute , 2008, Cell Death and Differentiation.

[104]  V. Palombella,et al.  IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells , 2008, Cancer Chemotherapy and Pharmacology.

[105]  K. Vousden,et al.  Ubiquitination and Degradation of Mutant p53 , 2007, Molecular and Cellular Biology.

[106]  Richard Pazdur,et al.  FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. , 2007, The oncologist.

[107]  Min Gyu Lee,et al.  p53 is regulated by the lysine demethylase LSD1 , 2007, Nature.

[108]  L. Ellisen,et al.  p63 and p73 in human cancer: defining the network , 2007, Oncogene.

[109]  Ying Feng,et al.  Supplemental Data P53-mediated Activation of Mirna34 Candidate Tumor-suppressor Genes , 2022 .

[110]  M. Hollstein,et al.  p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM , 2007, Nature Cell Biology.

[111]  Stefano Piccolo,et al.  Integration of TGF-ß and Ras/MAPK Signaling Through p53 Phosphorylation , 2007, Science.

[112]  Yi Tang,et al.  Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. , 2006, Molecular cell.

[113]  Ronen Marmorstein,et al.  Acetylation of the p53 DNA-binding domain regulates apoptosis induction. , 2006, Molecular cell.

[114]  M. Hollstein,et al.  Ser46 Phosphorylation Regulates p53-Dependent Apoptosis and Replicative Senescence , 2006, Cell cycle.

[115]  P. B. Chock,et al.  Expression of SUMO-2/3 Induced Senescence through p53- and pRB-mediated Pathways* , 2006, Journal of Biological Chemistry.

[116]  S. Berger,et al.  Repression of p53 activity by Smyd2-mediated methylation , 2006, Nature.

[117]  A. Yang,et al.  p63 protects the female germ line during meiotic arrest , 2006, Nature.

[118]  Giulia Piaggio,et al.  Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. , 2006, Cancer cell.

[119]  G. Wahl,et al.  A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. , 2006, Cancer cell.

[120]  Horst Kessler,et al.  WT p53, but Not Tumor-derived Mutants, Bind to Bcl2 via the DNA Binding Domain and Induce Mitochondrial Permeabilization* , 2006, Journal of Biological Chemistry.

[121]  Ken Garber,et al.  China approves world's first oncolytic virus therapy for cancer treatment. , 2006, Journal of the National Cancer Institute.

[122]  Xinbin Chen,et al.  The Unique NH2-terminally Deleted (ΔN) Residues, the PXXP Motif, and the PPXY Motif Are Required for the Transcriptional Activity of the ΔN Variant of p63* , 2006, Journal of Biological Chemistry.

[123]  M. Scian,et al.  Tumor-Derived p53 Mutants Induce NF-κB2 Gene Expression , 2005, Molecular and Cellular Biology.

[124]  P. Pandolfi,et al.  The promyelocytic leukaemia protein tumour suppressor functions as a transcriptional regulator of p63 , 2005, Oncogene.

[125]  David P Lane,et al.  p53 isoforms can regulate p53 transcriptional activity. , 2005, Genes & development.

[126]  K. Wiman,et al.  Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs* , 2005, Journal of Biological Chemistry.

[127]  T. Libermann,et al.  Blockage of NF-κB Induces Serine 15 Phosphorylation of Mutant p53 by JNK Kinase in Prostate Cancer Cells , 2005 .

[128]  W. El-Deiry,et al.  Phosphorylation of p21 in G2/M Promotes Cyclin B-Cdc2 Kinase Activity , 2005, Molecular and Cellular Biology.

[129]  V. Rotter,et al.  Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function , 2004, Cancer Research.

[130]  James M. Roberts,et al.  Living with or without cyclins and cyclin-dependent kinases. , 2004, Genes & development.

[131]  M. Kulesz-Martin,et al.  Facilitated search for specific genomic targets by p53 c-terminal basic DNA binding domain , 2004, Cancer biology & therapy.

[132]  Zigang Dong,et al.  Post-translational modification of p53 in tumorigenesis , 2004, Nature Reviews Cancer.

[133]  M. Matsumoto,et al.  Prognostic Significance of Serine 392 Phosphorylation in Overexpressed p53 Protein in Human Esophageal Squamous Cell Carcinoma , 2004, Oncology.

[134]  Xin Lu,et al.  Ser392 Phosphorylation Regulates the Oncogenic Function of Mutant p53 , 2004, Cancer Research.

[135]  D. Lane,et al.  Mdm2-Mediated NEDD8 Conjugation of p53 Inhibits Its Transcriptional Activity , 2004, Cell.

[136]  U. Moll,et al.  p63 and p73: roles in development and tumor formation. , 2004, Molecular cancer research : MCR.

[137]  Xinbin Chen,et al.  Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes , 2004, Oncogene.

[138]  D. Green,et al.  p73 Induces Apoptosis via PUMA Transactivation and Bax Mitochondrial Translocation* , 2004, Journal of Biological Chemistry.

[139]  Martin Schuler,et al.  Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis , 2004, Science.

[140]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[141]  Muyang Li,et al.  Mono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2 , 2003, Science.

[142]  E. Appella,et al.  Phosphorylation Site Interdependence of Human p53 Post-translational Modifications in Response to Stress* , 2003, Journal of Biological Chemistry.

[143]  Jiandong Chen,et al.  MDM2-ARF complex regulates p53 sumoylation , 2003, Oncogene.

[144]  D. Lane,et al.  Improving cancer therapy by non-genotoxic activation of p53. , 2003, European journal of cancer.

[145]  Guillermina Lozano,et al.  Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation , 2003, Cell.

[146]  Petr Pancoska,et al.  p53 has a direct apoptogenic role at the mitochondria. , 2003, Molecular cell.

[147]  Stewart N Loh,et al.  Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain. , 2003, Biochemistry.

[148]  Jiandong Chen,et al.  Phosphorylation and hsp90 Binding Mediate Heat Shock Stabilization of p53* , 2003, The Journal of Biological Chemistry.

[149]  Muyang Li,et al.  Acetylation of p53 Inhibits Its Ubiquitination by Mdm2* , 2002, The Journal of Biological Chemistry.

[150]  Tong Tong,et al.  GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity , 2002, Oncogene.

[151]  Gideon Rechavi,et al.  Identification of Direct p73 Target Genes Combining DNA Microarray and Chromatin Immunoprecipitation Analyses* , 2002, The Journal of Biological Chemistry.

[152]  Joanna K. Sax,et al.  BID regulation by p53 contributes to chemosensitivity , 2002, Nature Cell Biology.

[153]  Annick Harel-Bellan,et al.  Synthetic small inhibiting RNAs: Efficient tools to inactivate oncogenic mutations and restore p53 pathways , 2002 .

[154]  K. Tsai,et al.  p63 and p73 are required for p53-dependent apoptosis in response to DNA damage , 2002, Nature.

[155]  U. Moll,et al.  Nuclear degradation of p53 occurs during down‐regulation of the p53 response after DNA damage , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[156]  Galina Selivanova,et al.  Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound , 2002, Nature Medicine.

[157]  C. Cordon-Cardo,et al.  p63 expression profiles in human normal and tumor tissues. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[158]  C. Prives,et al.  The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells , 2002, Oncogene.

[159]  Stephen N. Jones,et al.  p53 mutant mice that display early ageing-associated phenotypes , 2002, Nature.

[160]  W. El-Deiry,et al.  The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis , 2002, Cancer biology & therapy.

[161]  S. Berger,et al.  Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. , 2001, Molecular cell.

[162]  Jiandong Chen,et al.  Inhibition of MDM2 by hsp90 Contributes to Mutant p53 Stabilization* , 2001, The Journal of Biological Chemistry.

[163]  Daxi Sun,et al.  Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1* , 2001, The Journal of Biological Chemistry.

[164]  J. Espinosa,et al.  Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. , 2001, Molecular cell.

[165]  C. Harris,et al.  Distinct pattern of p53 phosphorylation in human tumors , 2001, Oncogene.

[166]  Ettore Appella,et al.  p300/CBP‐mediated p53 acetylation is commonly induced by p53‐activating agents and inhibited by MDM2 , 2001, The EMBO journal.

[167]  A. Levine,et al.  A Role for the Polyproline Domain of p53 in Its Regulation by Mdm2* , 2001, The Journal of Biological Chemistry.

[168]  Wei Zhang,et al.  DNA damage-induced phosphorylation of p53 at serine 20 correlates with p21 and Mdm-2 induction in vivo , 2000, Oncogene.

[169]  R. Morimoto,et al.  Role of the heat shock response and molecular chaperones in oncogenesis and cell death. , 2000, Journal of the National Cancer Institute.

[170]  A. Fornace,et al.  Death and decoy receptors and p53-mediated apoptosis , 2000, Leukemia.

[171]  A. Yang,et al.  p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours , 2000, Nature.

[172]  Zhi-Min Yuan,et al.  Identification of a Sequence Element from p53 That Signals for Mdm2-Targeted Degradation , 2000, Molecular and Cellular Biology.

[173]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.

[174]  E. Stavridi,et al.  Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[175]  R. Hay,et al.  SUMO‐1 modification activates the transcriptional response of p53 , 1999, The EMBO journal.

[176]  M. Nakanishi,et al.  Direct interaction of p21 cyclin-dependent kinase inhibitor with the retinoblastoma tumor suppressor protein. , 1999, Biochemical and biophysical research communications.

[177]  T. Davison,et al.  p73 and p63 Are Homotetramers Capable of Weak Heterotypic Interactions with Each Other but Not with p53* , 1999, The Journal of Biological Chemistry.

[178]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[179]  C. Maki.  Oligomerization Is Required for p53 to be Efficiently Ubiquitinated by MDM2* , 1999, The Journal of Biological Chemistry.

[180]  Christopher P. Crum,et al.  p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development , 1999, Nature.

[181]  C. Harris,et al.  GADD45 induction of a G2/M cell cycle checkpoint. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[182]  Y Taya,et al.  A role for ATR in the DNA damage-induced phosphorylation of p53. , 1999, Genes & development.

[183]  S. Leach,et al.  p21Waf1/Cip1 Inhibition of Cyclin E/Cdk2 Activity Prevents Endoreduplication after Mitotic Spindle Disruption , 1999, Molecular and Cellular Biology.

[184]  G. Morris,et al.  p53-Mediated Regulation of Proliferating Cell Nuclear Antigen Expression in Cells Exposed to Ionizing Radiation , 1999, Molecular and Cellular Biology.

[185]  J U Bowie,et al.  p53 Family members p63 and p73 are SAM domain‐containing proteins , 1999, Protein science : a publication of the Protein Society.

[186]  F. Goodrum,et al.  p53 Status Does Not Determine Outcome of E1B 55-Kilodalton Mutant Adenovirus Lytic Infection , 1998, Journal of Virology.

[187]  K. Sakaguchi,et al.  DNA damage activates p53 through a phosphorylation-acetylation cascade. , 1998, Genes & development.

[188]  A. Yang,et al.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.

[189]  L. Bracco,et al.  The requirement for the p53 proline‐rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression , 1998, The EMBO journal.

[190]  J. Cleveland,et al.  Activation of c-myc Gene Expression by Tumor-Derived p53 Mutants Requires a Discrete C-Terminal Domain , 1998, Molecular and Cellular Biology.

[191]  S. Deb,et al.  `Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain , 1998, Oncogene.

[192]  M. Montenarh,et al.  Fine mapping and regulation of the association of p53 with p34cdc2 , 1998, Oncogene.

[193]  G. Lozano,et al.  Mouse models dissect the role of p53 in cancer and development. , 1998, Seminars in cancer biology.

[194]  K. Kinzler,et al.  14-3-3σ Is a p53-Regulated Inhibitor of G2/M Progression , 1997 .

[195]  P. Tegtmeyer,et al.  Reciprocal interference between the sequence-specific core and nonspecific C-terminal DNA binding domains of p53: implications for regulation , 1997, Molecular and cellular biology.

[196]  Yoichi Taya,et al.  DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2 , 1997, Cell.

[197]  E. Schuetz,et al.  p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[198]  W. Kaelin,et al.  p73 is a human p53-related protein that can induce apoptosis , 1997, Nature.

[199]  Wei Gu,et al.  Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain , 1997, Cell.

[200]  G. Prendergast,et al.  The polyproline region of p53 is required to activate apoptosis but not growth arrest , 1997, Oncogene.

[201]  P. Sutphin,et al.  Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo , 1997, Oncogene.

[202]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[203]  A. Levine,et al.  A proline-rich motif in p53 is required for transactivation-independent growth arrest as induced by Gas1. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[204]  A. Levine,et al.  Identification of a novel p53 functional domain that is necessary for efficient growth suppression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[205]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[206]  C. Harris,et al.  Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. , 1996, Journal of the National Cancer Institute.

[207]  T. Halazonetis,et al.  Structure–based rescue of common tumor–derived p53 mutants , 1996, Nature Medicine.

[208]  A. Levine,et al.  The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[209]  S. Elledge,et al.  Inhibition of cyclin-dependent kinases by p21. , 1995, Molecular biology of the cell.

[210]  John Calvin Reed,et al.  Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. , 1994, Oncogene.

[211]  A. Levine,et al.  Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. , 1994, Genes & development.

[212]  T. Halazonetis,et al.  Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. , 1993, The EMBO journal.

[213]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[214]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[215]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[216]  D. Lane,et al.  Regulation of the specific DNA binding function of p53 , 1992, Cell.

[217]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[218]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[219]  K. Kinzler,et al.  Definition of a consensus binding site for p53 , 1992, Nature Genetics.

[220]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[221]  I. Pastan,et al.  Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. , 1992, Science.

[222]  D. Ledbetter,et al.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. , 1989, Science.

[223]  P. Chumakov,et al.  A variation in the structure of the protein-coding region of the human p53 gene. , 1988, Gene.

[224]  V. Rotter,et al.  Molecular basis for heterogeneity of the human p53 protein , 1986, Molecular and cellular biology.

[225]  L. Crawford,et al.  Characterization of the human p53 gene , 1986, Molecular and cellular biology.

[226]  R. Carroll,et al.  Mapping of phosphomonoester and apparent phosphodiester bonds of the oncogene product p53 from simian virus 40-transformed 3T3 cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[227]  M. Oren,et al.  Overproduction of p53 antigen makes established cells highly tumorigenic , 1985, Nature.

[228]  D. Givol,et al.  Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. , 1985, The EMBO journal.

[229]  V. Rotter,et al.  Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation , 1984, Nature.

[230]  P. Gruss,et al.  Participation of p53 cellular tumour antigen in transformation of normal embryonic cells , 1984, Nature.

[231]  J. Jenkins,et al.  Cloning and expression analysis of full length mouse cDNA sequences encoding the transformation associated protein p53. , 1984, Nucleic acids research.

[232]  V. Rotter.  p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[233]  V. Rotter,et al.  Increased concentration of an apparently identical cellular protein in cells transformed by either Abelson murine leukemia virus or other transforming agents , 1981, Journal of virology.

[234]  P. Goodfellow,et al.  Detection of a common feature in several human tumor cell lines--a 53,000-dalton protein. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[235]  A. Levine,et al.  Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells , 1979, Cell.

[236]  D. Lane,et al.  T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.